Fulcrum Therapeutics (FULC) Net Cash Flow (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Net Cash Flow data on record, last reported at -$147.3 million in Q1 2026.

  • On a quarterly basis, Net Cash Flow fell 818.5% to -$147.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $8.1 million, a 262.63% increase, with the full-year FY2025 number at $139.3 million, up 325.3% from a year prior.
  • Net Cash Flow reached -$147.3 million in Q1 2026 per FULC's latest filing, down from $150.5 million in the prior quarter.
  • Over the last five years, Net Cash Flow for FULC hit a ceiling of $150.5 million in Q4 2025 and a floor of -$147.3 million in Q1 2026.
  • A 5-year average of $879882.4 and a median of -$768000.0 in 2023 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: soared 6189.58% in 2024, then tumbled 818.5% in 2026.
  • Tracing FULC's Net Cash Flow over 5 years: stood at -$55.8 million in 2022, then skyrocketed by 91.91% to -$4.5 million in 2023, then tumbled by 219.19% to -$14.4 million in 2024, then soared by 1143.52% to $150.5 million in 2025, then tumbled by 197.88% to -$147.3 million in 2026.
  • Business Quant data shows Net Cash Flow for FULC at -$147.3 million in Q1 2026, $150.5 million in Q4 2025, and $4.5 million in Q3 2025.